Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Raquel Annoni (Sao Paulo, Brazil), Raquel Annoni, Ligia Couceiro, Silvio Barbosa, Tatiana Lancas, Salvatore Battaglia, Marisa Dolhnikoff, Pieter Hiemstra, Peter Sterk, Klaus Rabe, Thais Mauad. Versican and collagen-III expression in bronchial and pulmonary muscular arteries in COPD patients. Eur Respir J 2015; 46: Suppl. 59, 2446

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary vessels remodeling in COPD Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2006 - Clinical physiology Year: 2006 Expression of TGFβ-1 and TGFβ-1RII in pulmonary arteries of patients with severe COPD Source: Eur Respir J 2003; 22: Suppl. 45, 392s Year: 2003 The effect of pulmonary hypertension on aerobic exercise capacity in lung transplant candidates with advanced COPD Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Vascular endothelial dysfunction in chronic obstructive pulmonary disease: Comparison with bronchial asthma, and controls Source: International Congress 2016 – Systemic biomarkers Year: 2016 Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Pulmonary gene expression of tenascin-C and fibronectin in chronic obtructive pulmonary disease (COPD) Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Impact of exacerbations on pulmonary arterial enlargement in patients with chronic obstructive pulmonary disease Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Relation between pulmonary arterial remodeling and parenchymal disease in severe COPD and interstitial lung disease patients Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 microRNA profile in COPD patients with and without pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Effect of pulmonary hemodynamics on the prognosis of patients with emphysematous COPD after LVRS Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 The prevalence and characteristics of pulmonary hypertension in severe COPD Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 CT measured pulmonary artery to aorta ratio as a predictor of pulmonary hypertension in COPD Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD Source: Eur Respir J 2002; 19: 632-638 Year: 2002 The transcription factor slug is increased in pulmonary artery endothelial cells of COPD patients Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Pulmonary vascular remodelling in COPD versus bronchial asthma Source: Eur Respir J 2003; 22: Suppl. 45, 82s Year: 2003 Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity Source: Eur Respir J 2005; 26: 586-593 Year: 2005